ELV News & Events

In a regulatory filing, the company said, "Officers of Elevance Health expect to speak with investors and analysts over the next week. During these meetings, company officers will reaffirm adjusted shareholders' earnings for full year 2026 to be at least $25.50 per diluted share. The company also will reaffirm its 2026 benefit expense ratio guidance of 90.2% plus or minus 50 basis points."

Myomo (MYO) announced it has entered into its first among a series of expected network participation agreements with Elevance Health (ELV). The contracts, which include the Anthem-affiliated Commercial, Medicare Advantage, and Medicaid plans are expected to become effective on a market-by-market basis through the second quarter of 2026. Once complete, the addition of these 45M medical members will bring Myomo's total number of covered lives under commercial insurance plans to over 80M. These agreements are expected to expand access to Myomo's MyoPro powered arm and hand orthoses, while supporting affordability for plan members and their families on an in-network basis. "We are pleased to partner with Elevance Health's affiliated plans to bring the benefits of MyoPro to their members," said Dr. Harry Kovelman, Myomo's Chief Medical Officer. "This arrangement with Elevance reinforces our commitment to helping individuals regain function and independence through clinically proven, innovative technologies delivered in a cost-effective manner."

The company also reaffirmed its FY26 benefit expense ratio guidance of 90.2% +/- 50 basis points. This guidance was taken from a regulatory filing.

Elevance Health announced management changes "designed to simplify decision-making and strengthen execution across Carelon and Health Benefits." As part of these changes, Mark Kaye, executive VP and CFO, will expand his responsibilities to include oversight of Carelon, the company's healthcare services operations including pharmacy services, behavioral health, value-based care, and care delivery capabilities. Felicia Norwood, executive VP and Chief Health Benefits Officer, will assume responsibility for the company's consolidated Health Benefits organization, bringing together the company's major Health Benefits businesses and core operating functions under a single accountable structure. Peter Haytaian has announced that he will transition from his role as executive VP and president of Carelon effective May 4, in order to devote more time to family commitments. Haytaian will serve the company as Special Advisor through December 31, to support an orderly leadership transition and ensure continuity across Carelon's operations and client and partner relationships.